Epoetin alfa (Procrit)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3][4]
Route: SC, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

History of changes in FDA indication

  • 6/1/1989: Initial FDA approval

Also known as

  • Generic names: Erythropoetin, Erythropoietin
  • Brand names: Ceriton, Dynepo, Epoch, Epofer, Epogen, Epogin, Epoimmun, Epomax, Epopen, Epox, Epoyet, Eprex, Eritrelan, Erypo, Erythrostim, Espo, Globuren, Hemapo, Hemax, LG Espogen, Procrit, Recormon, Vepox, Vintor, Wepox

References

  1. 1.0 1.1 1.2 Epoetin alfa (Procrit) package insert
  2. Epoetin alfa (Procrit) package insert (locally hosted backup)
  3. Procrit manufacturer's website
  4. As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
  5. Epoetin alfa (Procrit) patient instructions for use
  6. Epoetin alfa (Procrit) patient instructions for use (locally hosted backup)
  7. Epoetin alfa (Procrit) patient drug information (Chemocare)
  8. Epoetin alfa (Procrit) patient drug information (UpToDate)